SEC Form 4 · accession 0001232524-18-000029
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen L. Smith
Officer — EVP, R&D and CMO
Period of report
Feb 26, 2018
Accepted (ET)
Feb 28, 2018 · 5:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Feb 26, 2018 | F | 525 | $147.44 | D | 21,122 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
- F2Includes 59 ordinary shares acquired on May 31, 2017 and 61 ordinary shares acquired on November 30, 2017 under a Section 423 Employee Stock Purchase Plan.